EKF vs. MXCT, NIOX, CREO, IUG, NCYT, POLX, BELL, IHC, MHC, and AVO
Should you be buying EKF Diagnostics stock or one of its competitors? The main competitors of EKF Diagnostics include MaxCyte (MXCT), NIOX Group (NIOX), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Polarean Imaging (POLX), Belluscura (BELL), Inspiration Healthcare Group (IHC), MyHealthChecked (MHC), and Advanced Oncotherapy (AVO). These companies are all part of the "medical devices" industry.
EKF Diagnostics vs.
EKF Diagnostics (LON:EKF) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.
EKF Diagnostics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
EKF Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.
In the previous week, MaxCyte had 2 more articles in the media than EKF Diagnostics. MarketBeat recorded 2 mentions for MaxCyte and 0 mentions for EKF Diagnostics. EKF Diagnostics' average media sentiment score of -0.95 beat MaxCyte's score of -1.21 indicating that EKF Diagnostics is being referred to more favorably in the media.
EKF Diagnostics received 174 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.
70.3% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 70.5% of MaxCyte shares are owned by institutional investors. 5.2% of EKF Diagnostics shares are owned by company insiders. Comparatively, 1.5% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
EKF Diagnostics has a net margin of 9.37% compared to MaxCyte's net margin of -77.97%. EKF Diagnostics' return on equity of 7.58% beat MaxCyte's return on equity.
Summary
EKF Diagnostics beats MaxCyte on 11 of the 15 factors compared between the two stocks.
Get EKF Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EKF Diagnostics Competitors List
Related Companies and Tools
This page (LON:EKF) was last updated on 2/2/2025 by MarketBeat.com Staff
